An Open-label, Multicenter, Dose-escalation, Phase I Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), in Patients With Advanced and/or Metastatic Solid Tumors

Trial Profile

An Open-label, Multicenter, Dose-escalation, Phase I Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Alpha (FAP), in Patients With Advanced and/or Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs RO 6874281 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 24 Oct 2017 Planned End Date changed from 21 Sep 2019 to 28 May 2019.
    • 24 Oct 2017 Planned primary completion date changed from 21 Sep 2019 to 28 May 2019.
    • 25 Sep 2017 Planned End Date changed from 28 May 2019 to 21 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top